UK MHRA authorises BridgeBio's acoramidis for ATTR-CM
Acoramidis is an orally administered selective small molecule that stabilises transthyretin (TTR) by more than 90%.
This authorisation was supported by the outcomes from the pivotal ATTRibute-CM Phase III trial, which demonstrated cardiovascular benefits.
In the trial, the therapy's safety and efficacy were assessed in 632 symptomatic ATTR-CM subjects, and they were given either the therapy or a placebo for a 30-month period.
The primary clinical endpoints were met at month 30, showing a decrease in cardiovascular-related hospitalisations, preservation of functional capacity, improved survival and quality of life for subjects.
The therapy received the US Food and Drug Administration's (FDA) approval under the name Attruby in November 2024, and as Beyonttra by the European Commission (EC) in February 2025.
It was also approved in Japan by the Ministry of Health, Labour, and Welfare in March 2025.
In the UK, Bayer will manage all commercial activities for the therapy.
In March 2024, the company and Bayer entered a partnership granting the latter exclusive rights to commercialise the therapy in Europe.
According to the licencing agreement, BridgeBio will obtain tiered royalties starting in the low-thirties percent on UK sales after commercialisation efforts commence.
ATTR-CM is a fatal condition that causes heart failure due to restrictive cardiomyopathy.
BridgeBio Cardiorenal chief medical officer and president Jonathan Fox stated: 'We are proud to add another approval for acoramidis and thrilled that patients in the UK will now have access to Beyonttra since they are in great need of new disease-modifying treatments for their condition.
'We look forward to extending our collaboration with our European partner, Bayer, to serve ATTR-CM patients across the UK and the rest of Europe, and will continue to work towards reaching patients in as many regions as possible around the world."
"UK MHRA authorises BridgeBio's acoramidis for ATTR-CM" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 hours ago
- Yahoo
Manufacturing issues at Novo facility disrupt Regeneron drug review
Regeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects separate regulatory delays for blockbuster ophthalmology drug Eylea HD due to problems at a Novo Nordisk-owned manufacturing site. The FDA uncovered the issues during an inspection of Catalent's filling plant in Bloomington, Indiana. Novo acquired the site as part of its $16.5bn acquisition of the CDMO in December 2024. Regeneron is a customer of Catalent specifically for filling vials of Eylea – the pharma company's lead drug. In its Q2 results report, Regeneron said that it expects FDA regulatory decisions to be delayed for Eylea HD, the high-dose brand of Eylea in the US. The company is seeking approvals for every-four-week dosing in a pre-filled syringe and for the treatment of macular edema following retinal vein occlusion. Regeneron confirmed the inspection was not specific to Eylea HD, a drug it co-developed with Bayer. There was no date given for the PDUFA dates, which were originally slated for this month. The delays further weaken Regeneron's position in the eye disease market, which has been significantly eroded by Roche's rival drug Vabysmo (faricimab). Eylea's sales dropped 39% to $754 in the US in Q2, meaning it has now lost blockbuster status in the country, though the revenue drop was also caused by the pickup in sales of its high-dose version. Regeneron hopes Eylea HD – whose sales grew 29% this quarter – will help the company regain market share from Roche. Despite mixed results for its Eylea brand, Regeneron's total Q2 sales grew 4% to $3.68bn. Shortcomings at the Bloomington facility resulted in an FDA complete response letter (CRL) for Regeneron's cancer bispecific antibody odronextamab. The pharma company had been seeking a place in the relapsed/refractory follicular lymphoma market for the drug, though the Catalent Indiana site inspection meant the FDA declined to issue approval. The latest CRL means odronextamab has now been rejected a second time by the FDA, the previous decision made due to clinical data concerns in March 2024. Novo has discussed the findings with the FDA and is expected to submit its response next week, while Regeneron confirmed it has made alternate arrangements with third-party fillers. Though new timelines were not given for odronextamab's new filing or Eylea HD's updated PDUFA dates, Regeneron predicts a fast resolution. In a conference call on 1 August, Regeneron CEO Len Schleifer played down the severity of observations made during the FDA inspection. Schleifer commented that the FDA did not request structural changes, adding that the 'procedural' issues will not last long. Regeneron's problems with Catalent's filling site are not unexpected. Before Novo arrived as owners, issues at the plant caused a two month-delay for Eylea HD's FDA approval decision in 2023. In November 2024, the FDA also found quality control lapses at the facility, including discovery of a "pest" on the manufacturing line. The Indiana plant, which has a total area of 950,000 square feet, has received sizeable investments over the past few years for expansion. The site is the main supplier of fill-finish work for Novo Nordisk's billion-dollar weight loss drug Wegovy (semaglutide). Schleifer added in the conference call that the facility was involved in the production of 70 billion doses last year, conducting business 'with the vast majority of the top bio-pharmaceutical companies in the world.' As a result, Schleifer added that Regeneron may not be the only company affected by the inspection. 'I believe that we may not be the only PDUFA that's in snare because they do work for virtually all the biopharmaceutical companies,' he commented. "Manufacturing issues at Novo facility disrupt Regeneron drug review" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
2 days ago
- Business Insider
Kepler Capital Remains a Buy on Bayer (0P6S)
Kepler Capital analyst Christian Faitz maintained a Buy rating on Bayer on August 1 and set a price target of €33.00. The company's shares closed last Friday at €28.63. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Faitz covers the Basic Materials sector, focusing on stocks such as BASF SE, Wacker Chemie AG, and Akzo Nobel NV. According to TipRanks, Faitz has an average return of 8.1% and a 50.36% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bayer with a €27.73 average price target. The company has a one-year high of €31.04 and a one-year low of €18.37. Currently, Bayer has an average volume of 1.54M.
Newsweek
4 days ago
- Newsweek
Kelly Fanning on Redefining Leadership—and Balance—for Working Moms
While women have made significant strides in the workplace, inequities still remain. One of those areas includes the burden of home and career life balance that women undertake. Women make up nearly half of the U.S. workforce but still take on a larger share of household responsibilities. The 2022 American Time Use Survey from the Bureau of Labor Statistics found that women spend more time on average on household activities and child care than men. The Gender Equality Policy Institute's analysis of the ATU survey found that women who work full time do 1.8 times as much housework as men who work full time. Women who work part-time do 2.5 times as much housework as their male counterparts. Among full-time working parents, women do 1.6 times as much child care and household work as fathers. Part-time working mothers do 2.4 times as much child care and household labor as part-time working fathers. Kelly Fanning is on a mission to change corporate culture by normalizing those struggles that many working moms face. Fanning started her career at Johnson & Johnson, where she rose in ranks over 15 years from field sales to corporate leadership. She said that starting from the ground up in retail was the origin of her passion for consumer products, telling Newsweek that this experience brought her close to the shopper. About a decade into her career, she moved out of the field into the corporate side of the business. That path was through marketing, which meant getting her MBA at Northeastern part-time from 2009 to 2011. Fanning said this move was the biggest career step she had made. "When I went into marketing, that's the center of running the profit and loss statement, or the P and L, for the company and so it was an incredible opportunity to see the inside of an organization in a way that I had never seen before," she said. "But it also refilled my passion for the consumer, because it's so insight-based and consumer-based when you build a marketing campaign." She worked as a sales strategy manager and senior brand manager before becoming the director of marketing and sales strategy in 2016. After a stint as the chief of staff and strategy initiatives for the North America president, and the birth of her second son, Fanning took on the role of senior director of consumer strategy for the skin care and beauty division of Johnson & Johnson. In 2019, Fanning left the company to work at Bayer for about five years. She said she was brought on to turn around teams. But she missed the culture and the beauty industry she fell in love with. After reaching out to her mentors, she left Bayer for The Estee Lauder Company as the senior vice president and general manager for Clinique, North America. She now oversees brands like Clinique, Origins and Dr. Jart+. Women's Global Impact: Kelly Fanning Women's Global Impact: Kelly Fanning Newsweek Illustration With two young sons and a husband who also works full-time, Fanning knows a thing or two about balance. "A lot of the times when I speak at events, I give some perspective [that] both the spouses can do it," she said. "You can both have great careers and make it work. Along the way, you make sacrifices and you tend to race to the calendar for first-come, first-served." She is also the first to admit that being a working parent, while rewarding, is not easy. Her passion for her work in brand marketing drives her, even in those more difficult moments. She commutes into New York City from northern New Jersey because it's important for her to be in the office. But that also means she might miss a school play or a baseball game. "I've learned too late in life about finding the balance of passion and performance," she said. "I think about it in the sense of debits and credits – there are days where I'm the best leader [at work] and I'm not as great as a mom, and there are days where I'm the best mom, I can't put in as much [at work]. It's all about the longer-term performance on both." In corporate America, many women believe there is a culture that appears to treat working mothers and fathers differently. A PEW study found that women earned an average of 85 percent of what men earned in 2024. Of the women surveyed for this report, 45 percent said a major contributor to the prevalent wage gap is the choices that women make about how to balance work and family. Women, according to PEW, are more likely to feel "a great deal of pressure" to focus on responsibilities at home, when compared to men. Fanning is no stranger to this feeling and makes it a point to be open and direct with managers and colleagues in the workplace. When she interviewed for her current role, she asked how commuting and family commitments would fit with the job expectations. She has been honest about having to leave in the middle of a meeting to catch a train back home or pass something off because she needs to attend her son's graduation at 9 a.m. "I think that you have to be strong enough to protect your time, to protect your schedule, and you have to be really open with others that, whether you're a working caregiver or whatever it is, everyone's time is the most valuable thing we have," she said. "We have to be able to push back and not worry and overthink it." Maintaining that balance means making the most of her time. Because it is limited, Fanning said her 30-minute impact might have to be as much as another person's one-hour impact. Being open about the struggles of being a working parent has also led Fanning to be passed over for opportunities like traveling for a work trip because colleagues thought she wouldn't want to be pulled away from her family. She noted that this type of behavior is more common with women in the workplace, as they are still seen as the primary caregivers. "I want to make the choice not to travel, versus someone else making that choice for me," she said. "And it's really important that as female leaders, we speak up to that in particular [because] not asking me to go on that trip wasn't done because they didn't want me to go. It was done because they thought they were doing me a favor, so I didn't have to say no. And I always want to be seen as having the ability and the strength to say no." Fanning wants to take the stigma and the guilt out of those decisions because she said the choice to attend a family event shouldn't feel like a hard choice. As she's moved up in leadership, Fanning has led by example and been vocal in the workplace to support other female colleagues and establish an inclusive, supportive and flexible culture. "Culturally, to have managers and leaders who say, 'no, go [to the graduation]' is so great and reinforces the positivity and takes that [stigma] away," she said. "It's super important to shape that culture and make it the norm." There have been times when Fanning has repeated in several meetings that she won't be available on a certain day because she has a family obligation. That way, when an expecting parent is faced with that choice in the future, they feel comfortable making it. Something Fanning often shares with peers is to take the aspects you love about leadership and culture from previous organizations and implement those bits where you can at your current job. "One of my biggest jobs as a leader is to set a culture and tone in which I want to work in," she said. "You can pay it forward and make the next organization, the next generation better." Mentorship has played a major role in Fanning's career. She remembers when she felt insecure about her ability to meet the challenge of a new role, and a mentor told her, "They would never have put you in that job if they didn't think you could do it." "I think sometimes you feel like you're going to fail, and when you realize that an organization, your leadership team, is there to make you succeed, just that shift in mindset, I wish I would have known that earlier in my career," she said. "So often you feel like 'oh my gosh, I'm going to fail, what if I fail?' and if you could flip that to say 'they put me here to succeed. What is it going to feel like when I succeed?' It's such a pivot on that emotion that I love to share with the next generation." Fanning will join Newsweek at this year's inaugural Women's Global Impact forum. The August 5 event, hosted at Newsweek's headquarters in New York City, will bring together some of the world's top female executives and connect them with rising stars across industries and job functions. For more information on the event and entry guidelines, please visit the Women's Global Impact homepage.
